Icon (NASDAQ:ICLR – Get Free Report) and OmniAb (NASDAQ:OABI – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.
Analyst Ratings
This is a summary of recent ratings for Icon and OmniAb, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Icon | 1 | 9 | 9 | 1 | 2.50 |
| OmniAb | 1 | 0 | 3 | 0 | 2.50 |
Icon currently has a consensus target price of $213.76, suggesting a potential upside of 9.82%. OmniAb has a consensus target price of $11.50, suggesting a potential upside of 134.22%. Given OmniAb’s higher possible upside, analysts plainly believe OmniAb is more favorable than Icon.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Icon | 5.45% | 7.73% | 4.39% |
| OmniAb | -108.11% | -16.74% | -14.79% |
Risk and Volatility
Icon has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, OmniAb has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.
Insider and Institutional Ownership
95.6% of Icon shares are owned by institutional investors. Comparatively, 72.1% of OmniAb shares are owned by institutional investors. 44.0% of Icon shares are owned by company insiders. Comparatively, 9.8% of OmniAb shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Icon and OmniAb”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Icon | $8.23 billion | 1.81 | $229.34 million | $5.81 | 33.50 |
| OmniAb | $18.67 million | 38.36 | -$64.78 million | ($0.34) | -14.44 |
Icon has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.
Summary
Icon beats OmniAb on 12 of the 14 factors compared between the two stocks.
About Icon
ICON plc is a global contract research organization (CRO) that provides outsourced development services to pharmaceutical, biotechnology, medical device and government organizations. Its work supports the development of medicines and other healthcare products from early research through clinical trials and regulatory submission. The company’s services include clinical trial design and management, data management and biostatistics, regulatory support, laboratory services, medical imaging and patient recruitment.
About OmniAb
OmniAb, Inc. is a biotechnology company that develops antibody discovery technologies for use in creating therapeutic medicines. It works with pharmaceutical and biotechnology companies to identify and advance antibody candidates for potential drug development. Its platform includes genetically engineered animals that can produce antibodies with human characteristics, along with related discovery and screening technologies. These tools are designed to help partners find antibodies for a range of therapeutic targets and applications.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.
